Your browser is not supported. Please upgrade to a modern browser in order to use all the features of the UKHC web application: Firefox | Chrome | Microsoft Edge
Skip to main content
close menu
close menu

Search UK HealthCare

Molecular Tumor Board

The Markey Cancer Center Molecular Tumor Board (MTB) is a statewide service available to physicians at UK HealthCare and regional affiliates.

The MTB provides a forum for expert clinicians, pathologists and scientists to discuss and analyze tumor genotypes and molecular abnormalities in order to recommend patient specific targeted therapies. 

The MTB is intended to supplement oncology tumor boards and includes a broad range of expert panel members.

Clinicians can order a genomic report and submit a case study to be presented for review by the MTB during their twice monthly meetings. For an overview of the MTB, download the referral flyer below.

Download our referral flyer (PDF, 295 KB

  • Meetings

    The Molecular Tumor Board (MTB) meets:

    • 12 p.m.
    • Every first and third Tuesday

    MTB meetings are currently held via Zoom. Please email either Abigail Anderson, PhD or Rebecca Carpenter for Zoom details to attend.

    Some MTB meetings will include a 15-minute informational update on Precision Medicine. See Schedule for Topics and Speakers.

    To schedule a case presentation, review the details in the Case Submission section. All cases must be submitted to MTB seven days prior to meeting date.

    2022 MTB Meeting Schedule

    Month Day / Tues Location
    January 4 Zoom
    January 18 Zoom
    February 1 Zoom
    February 15 Zoom
    March 1 Zoom
    March 15 Zoom
    April 5 Zoom
    April 19 Zoom
    May 3 Zoom
    May 17 Zoom
    June 7 Zoom
    June 21 Zoom
    July 5 Zoom
    July 19 Zoom
    August 2 Zoom
    August 16 Zoom
    September 6 Zoom
    September 20 Zoom
    October 4 Zoom
    October 18 Zoom
    November 1 Zoom
    November 15 Zoom
    December 6 Zoom
    December 20 Zoom

    Continuing Medical Education (CME)

    If clinicians or pharmacists want to obtain CE Credit for this meeting, they must attend the meeting in person or via teleconference, then enter the provided access code on the CE Central website. Any questions or concerns regarding CE Credit can be directed to the MTB Manager at

    Policy on Disclosure

    It is the policy of the Markey Cancer Center that the faculty, authors, planners and other persons who may influence the content of this CME activity disclose all relevant financial relationships with commercial interests in order to allow CME staff to identify and resolve any potential conflicts of interest. Faculty must also disclose any planned discussions of unlabeled/unapproved uses of drugs or devices during their presentation.

  • Case Submission

    Cases must be submitted at least seven days prior to the meeting date.

    Genomics reports from UK HealthCare or external sources (Foundation, MATCH, etc.) can be submitted.

    A patient's genomic report is required for case submission. Please see how to order a genomic report through UK HealthCare under Order a Genomic Report below. 

    If you already have a genomic report, fill out the case submission form online, or download the form here.

    The patient’s genomic report can be sent to MTB by email.

    When the case submission and genomic report are received, the MTB manager will schedule the case for presentation and invite the treating clinician to the meeting.

    Treatment recommendations will be discussed at the MTB meeting. Recommendation letters will be faxed and/or mailed or uploaded into the electronic health record per the preference of the submitting physician. Specify method of results reporting on the case submission form.

    Note: There is no cost to submit a case to the Markey Cancer Center Molecular Tumor Board.

  • Research

    The Molecular Tumor Board currently has two prospective clinical trials evaluating integration of Precision Medicine into cancer therapeutics.

    • Part 1:  A prospective observational cohort study evaluating outcomes of genomic testing in patients with poor prognosis cancer.
    • Part 2: A therapeutic phase 2 sub-study evaluating genomic testing in human cancer and outcomes of targeted therapies recommended by an institutional multidisciplinary molecular tumor board in patients with poor prognosis cancer.

    Researchers who are interested in using the data or specimen collected under these protocols must complete the data request form.

  • Contact Us

    Directors Site Leaders 

    Jill Kolesar, PharmD

    Professor, College of Pharmacy

    Department of Pharmacy Practice and Science

    Chandler Park, MD, FACP

    Research Medical Director at Hardin Memorial Hospital, Central Kentucky Region

    UK Markey Cancer Center Research Network

    Rachel Ware Miller, MD

    Associate Professor, Division of Gynecologic Oncology

    Department of Obstetrics and Gynecology

    Administrative Office  

    Abigail Anderson, PhD,
    MTB Project Manager

    Rebecca Carpenter,
    Administrative Support Associate